BACKGROUND: Angiosarcomas (AS) are rare tumors of vascular origin with a variable behavior and overall poor prognosis. We sought to assess the outcomes of patients treated for metastatic disease. METHODS: We performed a retrospective analysis of 119 patients treated for metastatic AS. Outcomes and efficacy measurements of the first and subsequent lines of treatment were analyzed. RESULTS: Median age was 61 years, and the most frequent primary sites were chest wall/breast (31%), viscera (22%) and head/neck (20%). Seventy-three (61%) and 46 (39%) patients received ≥ 2 and ≥ 3 lines of therapy, respectively. The most commonly used agents included taxanes and anthracyclines. Median overall survival was 12.1 months. Median times to tumor progression were 3.5 months for first line, 3.7 months for second line and 2.7 months for third line. Among 48 patients evaluable per RECIST, the overall response rate to first line was 30% and <10% in subsequent lines. Doxorubicin, liposomal doxorubicin and taxanes resulted in similar response rates and survival, and there was no apparent benefit for combination chemotherapy. CONCLUSION: Despite reasonable response rates in the first-line setting, benefit from systemic therapy is short-lived in metastatic AS, and outcomes are poor. Doxorubicin, liposomal doxorubicin and taxanes are reasonable and appropriate choices for monotherapy.
BACKGROUND:Angiosarcomas (AS) are rare tumors of vascular origin with a variable behavior and overall poor prognosis. We sought to assess the outcomes of patients treated for metastatic disease. METHODS: We performed a retrospective analysis of 119 patients treated for metastatic AS. Outcomes and efficacy measurements of the first and subsequent lines of treatment were analyzed. RESULTS: Median age was 61 years, and the most frequent primary sites were chest wall/breast (31%), viscera (22%) and head/neck (20%). Seventy-three (61%) and 46 (39%) patients received ≥ 2 and ≥ 3 lines of therapy, respectively. The most commonly used agents included taxanes and anthracyclines. Median overall survival was 12.1 months. Median times to tumor progression were 3.5 months for first line, 3.7 months for second line and 2.7 months for third line. Among 48 patients evaluable per RECIST, the overall response rate to first line was 30% and <10% in subsequent lines. Doxorubicin, liposomal doxorubicin and taxanes resulted in similar response rates and survival, and there was no apparent benefit for combination chemotherapy. CONCLUSION: Despite reasonable response rates in the first-line setting, benefit from systemic therapy is short-lived in metastatic AS, and outcomes are poor. Doxorubicin, liposomal doxorubicin and taxanes are reasonable and appropriate choices for monotherapy.
Authors: Mohamad Farid; Whee Sze Ong; Marcus Jin Fu Lee; Raaj Jeevan; Zhen Chong Ho; Alisa Noor Hidayah Sairi; Lay Tin Soh; Donald Poon; Jonathan Teh; Francis Chin; Melissa Teo; Richard Quek Journal: Oncology Date: 2013-08-31 Impact factor: 2.935
Authors: Matthew G Fury; Cristina R Antonescu; Kimberly J Van Zee; Murray F Brennan; Robert G Maki Journal: Cancer J Date: 2005 May-Jun Impact factor: 3.360
Authors: S Stacchiotti; E Palassini; R Sanfilippo; B Vincenzi; M G Arena; A M Bochicchio; P De Rosa; A Nuzzo; S Turano; C Morosi; A P Dei Tos; S Pilotti; P G Casali Journal: Ann Oncol Date: 2011-04-04 Impact factor: 32.976
Authors: Tianhua Guo; Lei Zhang; Ning-En Chang; Samuel Singer; Robert G Maki; Cristina R Antonescu Journal: Genes Chromosomes Cancer Date: 2011-01 Impact factor: 5.006
Authors: M Schlemmer; P Reichardt; J Verweij; J T Hartmann; I Judson; A Thyss; P C W Hogendoorn; S Marreaud; M Van Glabbeke; J Y Blay Journal: Eur J Cancer Date: 2008-09-02 Impact factor: 9.162
Authors: Timothy M Pawlik; Augusto F Paulino; Cornelius J McGinn; Laurence H Baker; Deborah S Cohen; Jeffery S Morris; Riley Rees; Vernon K Sondak Journal: Cancer Date: 2003-10-15 Impact factor: 6.860
Authors: Cristina R Antonescu; Akihiko Yoshida; Tianhuo Guo; Ning-En Chang; Lei Zhang; Narasimhan P Agaram; Li-Xuan Qin; Murray F Brennan; Samuel Singer; Robert G Maki Journal: Cancer Res Date: 2009-09-01 Impact factor: 12.701
Authors: Jason A Hanna; Catherine J Drummond; Matthew R Garcia; Jonathan C Go; David Finkelstein; Jerold E Rehg; Mark E Hatley Journal: Cancer Res Date: 2017-09-15 Impact factor: 12.701
Authors: M A Dickson; M R Mahoney; W D Tap; S P D'Angelo; M L Keohan; B A Van Tine; M Agulnik; L E Horvath; J S Nair; G K Schwartz Journal: Ann Oncol Date: 2016-08-08 Impact factor: 32.976
Authors: José Maurício Mota; Mariana Scaranti; Leonardo G Fonseca; Diego Araújo Tolói; Veridiana Pires de Camargo; Rodrigo Ramella Munhoz; Olavo Feher; Paulo M Hoff Journal: Case Rep Oncol Date: 2016-08-24
Authors: Jii Bum Lee; Beung-Chul Ahn; Seung Hyun Kim; Young Han Lee; Jung Woo Han; Min Kyung Jeon; Soo Hee Kim; Hyo Song Kim Journal: Future Sci OA Date: 2021-03-02